InVitria Successfully Completes National Institutes of Health Grant for Animal-Free Media Supplements

InVitria’s recombinant human serum albumin is completely animal-free and was developed with financial support from NIH through SBIR grant awards.

Fort Collins, CO November 30, 2011 – The National Institutes of Health (NIH) awarded InVitria a $725,000 Phase II, Small Business Innovation Research (SBIR) Grant to broaden the applications for InVitria’s recombinant human serum albumin product Cellastim®. The Phase II grant was awarded in 2009 as a two-year project, which was successfully completed on-time in 2011. “We are delighted that the objectives of the grant were achieved. The team exceeded those objectives and also implemented cGMP quality standards for manufacturing recombinant human serum albumin,” said Scott Deeter, President. “This is a significant step for our customers and the life science industry.”